52 related articles for article (PubMed ID: 32523354)
1. Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma.
Liu Z; Huang K; Wu Q; Zhou Q
Asian J Surg; 2024 Mar; 47(3):1505-1507. PubMed ID: 38071095
[No Abstract] [Full Text] [Related]
2. STRN::ALK, a novel fusion to foetal lung interstitial tumour.
Paoli C; Di Mauro I; Coulomb A; Benadiba J; Lecompte JF; Dadone-Montaudié B; Burel-Vandenbos F
Histopathology; 2024 Jun; ():. PubMed ID: 38859770
[No Abstract] [Full Text] [Related]
3. From spotlight to shadow: ALK inhibitor-induced acute liver failure in a patient with non-small cell lung cancer.
Juncu SŞ; Trifan AV; Minea H; Avram RI; Cojocariu C; Sîngeap AM
Arch Clin Cases; 2023; 10(4):160-163. PubMed ID: 38026106
[No Abstract] [Full Text] [Related]
4. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1.
Sievers P; Sill M; Blume C; Tauziede-Espariat A; Schrimpf D; Stichel D; Reuss DE; Dogan H; Hartmann C; Mawrin C; Hasselblatt M; Stummer W; Schick U; Hench J; Frank S; Ketter R; Schweizer L; Schittenhelm J; Puget S; Brandner S; Jaunmuktane Z; Küsters B; Abdullaev Z; Pekmezci M; Snuderl M; Ratliff M; Herold-Mende C; Unterberg A; Aldape K; Ellison DW; Wesseling P; Reifenberger G; Wick W; Perry A; Varlet P; Pfister SM; Jones DTW; von Deimling A; Sahm F;
Acta Neuropathol; 2021 Feb; 141(2):281-290. PubMed ID: 33319313
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract][Full Text] [Related]
6. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
7. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
8. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.
Niu X; Chuang JC; Berry GJ; Wakelee HA
Curr Treat Options Oncol; 2017 Nov; 18(12):71. PubMed ID: 29143897
[TBL] [Abstract][Full Text] [Related]
10. Responses to
Wang R; Qin J; Fan Y; Li Z; Chen C; Su W
Onco Targets Ther; 2020; 13():4183-4187. PubMed ID: 32523354
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
12. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
13. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
14. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
15. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
